Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030


LPG Tankers Market Growth & Trends

The global LPG tankers market size is anticipated to reach USD 286.48 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.4% from 2025 to 2030. Strong growth in shale gas production is likely to propel the market growth over the coming years. The volatility of crude oil prices coupled with developments in hydraulic fracturing and horizontal drilling methods resulted in major companies shifting their attention towards the production of oil and gas from shale rock. Change in focus towards the production of shale gas is further projected to enhance market growth over the estimated period. The Very Large Gas Carriers (VLGC) segment led the market in 2021.

However, the Large Gas Carrier (LGC) is anticipated to take over the forecast period by a small margin. Very large gas carriers are widely used for the transportation of liquified petroleum gas (LPG) for longer distances across various countries. Growing liquefied petroleum gas trade relationships between various regions, such as the Middle East and Asian countries, Western Africa and Europe, and the United States, is the major factor projected to boost the VLGC segment growth. The full-pressurized segment led the market in 2021 and will maintain its lead throughout the forecast period. The market is anticipated to have a steady growth in all segments as the amount of LPG transported increases.

The supply chain of the LPG and ancillary industries was affected due to the shutdown of production facilities, especially in Asia Pacific, as it was the epicenter of the COVID-19. The manufacturing and energy & power sectors globally experienced a considerable slowdown due to the COVID-19. In addition, local and international travel restrictions, quarantine requirements, and lockdowns further delayed shipments of LPG that were in process of being delivered. The market growth is determined by improved LPG trading around the globe. Shale gas extraction is likely to rise at a rapid pace, which will drive growth over the forecast years. Factors including capacity expansion of shale gas from untapped stocks enhanced global gas trade, and ongoing usage of liquefied petroleum gas as a cooking fuel is contributing to the development of the market for liquefied petroleum gas tankers.

LPG Tankers Market Report Highlights
  • In terms of revenue, the VLGC segment accounted for the maximum revenue share in 2024 and is projected to expand further at a steady growth rate over the forecast period.
  • The full-pressurized segment dominated the market and accounted for more than 32.5% of the global revenue share in 2024.
  • In 2024, Europe was the dominant regional market on account of the increasing demand for LPG.
  • Various strategic initiatives were recorded over the past few years to boost the growth of the market.
  • For instance, In August 2021 Ultragas ApS merged with Navigator gas and created a combined fleet of 56 ships. This merger was done to stay competitive in the market and reduce the current competition.
  • The liquified petroleum gas market is becoming increasingly centralized with a lot of mergers and acquisitions taking place between the players.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Indication
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Scleroderma Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Scleroderma Therapeutics Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Immunosuppressors
4.4.1. Immunosuppressors Market, 2018 - 2030 (USD Million)
4.5. Phosphodiesterase 5 inhibitors - PHA
4.5.1. Phosphodiesterase 5 inhibitors - PHA Market, 2018 - 2030 (USD Million)
4.6. Endothelin Receptor Antagonists
4.6.1. Endothelin Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.7. Prostacyclin Analogues
4.7.1. Prostacyclin Analogues Market, 2018 - 2030 (USD Million)
4.8. Calcium Channel Blockers
4.8.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
4.9. Analgesics
4.9.1. Analgesics Market, 2018 - 2030 (USD Million)
4.10. Calcium Channel Blockers
4.10.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
4.11. Others
4.11.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Scleroderma Therapeutics Market: Indication Business Analysis
5.1. Indication Market Share, 2024 & 2030
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
5.4. Systemic Scleroderma
5.4.1. Systemic Scleroderma Market, 2018 - 2030 (USD Million)
5.4.2. Morphea
5.4.2.1. Morphea Market, 2018 - 2030 (USD Million)
5.4.3. Linear
5.4.3.1. Linear Market, 2018 - 2030 (USD Million)
5.5. Localized Scleroderma
5.5.1. Localized Scleroderma Market, 2018 - 2030 (USD Million)
5.5.2. Diffuse Systemic Sclerosis
5.5.2.1. Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)
5.5.3. Limited Cutaneous Systemic Sclerosis Syndrome
5.5.3.1. Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)
Chapter 6. Scleroderma Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class and Indication
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Denmark Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Sweden Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Norway Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. Australia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. South Korea Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Scleroderma therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.8. MEA
6.8.1. MEA Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. F. Hoffman La-Roche Ltd
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Bristol-Myers Squibb Company
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Bayer AG
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Boehringer Ingelheim International GmbH
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Emerald Health Pharmaceuticals
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Sanofi
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Cytori Therapeutics Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Chemomab
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Corbus Pharmaceuticals Holdings, Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Calliditas Therapeutics AB
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings